Fierce Biotech July 15, 2022
Cancer patients are more likely to take part in clinical trials that use decentralized technologies, according to analysis by U.S. researchers.
The survey, conducted by American Cancer Society Cancer Action Network (ACS/CAN) researchers, looked at the impact “decentralization tools”—wearable and self-report systems, online portals, etc.—have on patient participation in drug trials.
The key finding is that decentralized technologies boost enrollment rates. According to the researchers, the majority of the 1,183 patients surveyed said they would be more likely to sign up to a study if the participation-related time and travel burdens were reduced.
“If given the opportunity to enroll in a cancer clinical trial that required travel farther than their regular care, a majority of respondents indicated that they would...
Today's Sponsors
Today's Sponsor